- Home
- BGIN vs PROK Comparison
BGIN vs PROK Comparison
Compare BGIN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGIN
- PROK
- Stock Information
- Founded
- BGIN 2019
- PROK 2015
- Country
- BGIN Singapore
- PROK United States
- Employees
- BGIN N/A
- PROK N/A
- Industry
- BGIN
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BGIN
- PROK Health Care
- Exchange
- BGIN Nasdaq
- PROK Nasdaq
- Market Cap
- BGIN 387.8M
- PROK 417.1M
- IPO Year
- BGIN 2025
- PROK N/A
- Fundamental
- Price
- BGIN $4.44
- PROK $3.04
- Analyst Decision
- BGIN
- PROK Strong Buy
- Analyst Count
- BGIN 0
- PROK 4
- Target Price
- BGIN N/A
- PROK $6.25
- AVG Volume (30 Days)
- BGIN 884.5K
- PROK 2.3M
- Earning Date
- BGIN 11-22-2025
- PROK 11-12-2025
- Dividend Yield
- BGIN N/A
- PROK N/A
- EPS Growth
- BGIN N/A
- PROK N/A
- EPS
- BGIN 0.61
- PROK N/A
- Revenue
- BGIN $302,277,581.00
- PROK $527,000.00
- Revenue This Year
- BGIN N/A
- PROK $471.74
- Revenue Next Year
- BGIN N/A
- PROK N/A
- P/E Ratio
- BGIN $7.26
- PROK N/A
- Revenue Growth
- BGIN 17.50
- PROK N/A
- 52 Week Low
- BGIN $3.81
- PROK $0.46
- 52 Week High
- BGIN $6.50
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- BGIN N/A
- PROK 52.26
- Support Level
- BGIN N/A
- PROK $3.05
- Resistance Level
- BGIN N/A
- PROK $3.48
- Average True Range (ATR)
- BGIN 0.00
- PROK 0.25
- MACD
- BGIN 0.00
- PROK -0.02
- Stochastic Oscillator
- BGIN 0.00
- PROK 35.30
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.